4.4 Review

Intradermal powder immunization with protein-containing vaccines

期刊

EXPERT REVIEW OF VACCINES
卷 12, 期 6, 页码 687-702

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.13.48

关键词

epidermal powder immunization; immunogenicity; intradermal injection; microparticles; needle-free

资金

  1. Novartis Vaccines
  2. GlaxoSmithKline
  3. Sanofi-Aventis
  4. Sanofi-Pasteur MSD
  5. Pfizer Vaccines
  6. Biotechnology and Biological Sciences Research Council (BBSRC)
  7. Wellcome Trust

向作者/读者索取更多资源

The central importance for global public health policy of delivering life-saving vaccines for all children makes the development of efficacious and safe needle-free alternatives to hypodermic needles, preferably in a thermostable form, a matter of pressing urgency. This paper comprehensively reviews past in vivo studies on intradermal powder immunization with vaccine formulations that do not require refrigeration. Particular emphasis is given to the immune response in relation to antigen adjuvantation. While needle-free intradermal delivery of vaccines induces a predominantly Th2-type immune response, adjuvants powerfully enhance and modulate the magnitude and nature of the elicited immune response at various effector sites.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据